Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FLGC NASDAQ:HOOK NASDAQ:INAB NASDAQ:KTTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLGCFlora Growth$3.35+7.7%$4.69$5.86▼$47.00$3.50M1.939,454 shs15,553 shsHOOKHOOKIPA Pharma$1.15$1.15$0.81▼$1.65$14.18M0.8511,089 shs431 shsINABIN8bio$1.42$1.52$1.17▼$2.73$13.98M0.2234,585 shs18,942 shsKTTAPasithea Therapeutics$0.55$0.65$0.28▼$2.06$13.71M0.291.63 million shs415,187 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLGCFlora Growth0.00%-2.33%-31.63%-40.39%-85.55%HOOKHOOKIPA Pharma0.00%0.00%0.00%0.00%-6.50%INABIN8bio0.00%+4.41%-7.79%-1.39%-34.26%KTTAPasithea Therapeutics0.00%+1.18%-11.32%-28.59%-26.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLGCFlora Growth$3.35+7.7%$4.69$5.86▼$47.00$3.50M1.939,454 shs15,553 shsHOOKHOOKIPA Pharma$1.15$1.15$0.81▼$1.65$14.18M0.8511,089 shs431 shsINABIN8bio$1.42$1.52$1.17▼$2.73$13.98M0.2234,585 shs18,942 shsKTTAPasithea Therapeutics$0.55$0.65$0.28▼$2.06$13.71M0.291.63 million shs415,187 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLGCFlora Growth0.00%-2.33%-31.63%-40.39%-85.55%HOOKHOOKIPA Pharma0.00%0.00%0.00%0.00%-6.50%INABIN8bio0.00%+4.41%-7.79%-1.39%-34.26%KTTAPasithea Therapeutics0.00%+1.18%-11.32%-28.59%-26.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFLGCFlora Growth 2.00Hold$30.00795.52% UpsideHOOKHOOKIPA Pharma 0.00N/AN/AN/AINABIN8bio 2.00Hold$4.00181.69% UpsideKTTAPasithea Therapeutics 2.00Hold$3.00445.65% UpsideCurrent Analyst Ratings BreakdownLatest FLGC, KTTA, INAB, and HOOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026KTTAPasithea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/16/2026KTTAPasithea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.006/4/2026INABIN8bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/1/2026KTTAPasithea Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/21/2026INABIN8bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026KTTAPasithea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.00(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFLGCFlora Growth$57.61M0.06N/AN/A$12.21 per share0.27HOOKHOOKIPA Pharma$9.35M1.52N/AN/A$4.25 per share0.27INABIN8bioN/AN/AN/AN/A$2.82 per shareN/AKTTAPasithea TherapeuticsN/AN/AN/AN/A$2.39 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFLGCFlora Growth-$15.91M-$32.49N/AN/AN/A-32.03%-64.02%-34.46%N/AHOOKHOOKIPA Pharma-$43.50M-$3.54N/AN/AN/A-785.66%-120.09%-77.14%8/7/2026 (Estimated)INABIN8bio-$19.44M-$2.61N/AN/AN/AN/A-96.39%-80.18%8/6/2026 (Estimated)KTTAPasithea Therapeutics-$20.43M-$2.08N/AN/AN/AN/A-57.44%-53.61%8/13/2026 (Estimated)Latest FLGC, KTTA, INAB, and HOOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026KTTAPasithea Therapeutics-$0.45-$0.12+$0.33-$0.12$0.10 millionN/A5/7/2026Q1 2026INABIN8bio-$0.59-$0.26+$0.33-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFLGCFlora GrowthN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/AINABIN8bioN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFLGCFlora GrowthN/A2.081.79HOOKHOOKIPA PharmaN/A3.613.61INABIN8bioN/A10.5010.50KTTAPasithea TherapeuticsN/A35.4135.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFLGCFlora Growth36.01%HOOKHOOKIPA Pharma63.88%INABIN8bio92.05%KTTAPasithea Therapeutics23.92%Insider OwnershipCompanyInsider OwnershipFLGCFlora Growth2.34%HOOKHOOKIPA Pharma3.30%INABIN8bio14.50%KTTAPasithea Therapeutics2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFLGCFlora Growth2801.05 million1.02 millionNot OptionableHOOKHOOKIPA Pharma16012.33 million11.79 millionOptionableINABIN8bio209.85 million8.42 millionNot OptionableKTTAPasithea Therapeutics324.94 million24.44 millionNot OptionableFLGC, KTTA, INAB, and HOOK HeadlinesRecent News About These CompaniesPasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF ...June 30, 2026 | finance.yahoo.comPasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol ExpansionJune 30, 2026 | globenewswire.comPasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical TrialJune 16, 2026 | globenewswire.comPasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF ConferenceJune 15, 2026 | finance.yahoo.comPasithea Therapeutics to Engage with NF1 Community at 2026 Children's Tumor Foundation Conference Following FDA Designations for PAS-004June 15, 2026 | quiverquant.comQPasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF ConferenceJune 15, 2026 | globenewswire.comPasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock NowJune 10, 2026 | zacks.comPasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)June 2, 2026 | globenewswire.comPasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical OfficerMay 4, 2026 | globenewswire.comIs Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?May 3, 2026 | finance.yahoo.comPasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)April 20, 2026 | markets.businessinsider.comPasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN ...April 1, 2026 | markets.businessinsider.comPasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant MorbidityApril 1, 2026 | globenewswire.comPasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference TranscriptFebruary 27, 2026 | seekingalpha.comPasithea Therapeutics Corp. to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026February 17, 2026 | quiverquant.comQPasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 17, 2026 | globenewswire.comPasithea Therapeutics Shareholders Approve Expanded Equity AuthorizationJanuary 28, 2026 | tipranks.comPasithea Therapeutics Updates Clinical Trial Timelines for PAS-004 in Neurofibromatosis and Advanced CancerJanuary 13, 2026 | quiverquant.comQPasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release TimelinesJanuary 13, 2026 | globenewswire.comPasithea Therapeutics (KTTA) price target increased by 50.00% to 3.06December 21, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 20265 High-Yield Stocks With Analyst Support and Room to RunBy Thomas Hughes | June 16, 2026EVs Are Big Winners of the Iran War—Just Not American OnesBy Jessica Mitacek | June 24, 20263 Energy Stocks Built for the AI Power Boom—And BeyondBy Bridget Bennett | June 8, 2026Is Lennar Finally Turning the Corner After Its Housing Slump?By Leo Miller | June 16, 2026FLGC, KTTA, INAB, and HOOK Company DescriptionsFlora Growth NASDAQ:FLGC$3.35 +0.24 (+7.72%) As of 07/2/2026Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.HOOKIPA Pharma NASDAQ:HOOK$1.15 0.00 (0.00%) As of 06/2/2026HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.IN8bio NASDAQ:INAB$1.42 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$1.42 0.00 (-0.35%) As of 07/2/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications. Pasithea Therapeutics NASDAQ:KTTA$0.55 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$0.54 -0.01 (-2.33%) As of 07/2/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
